高危局限性肾癌肾切除术后辅助帕唑帕尼III期试验
这项III期随机试验评估帕唑帕尼与安慰剂在肾切除术后高复发风险的局部晚期肾细胞癌患者中的疗效与安全性,共纳入1,538例,主要终点为帕唑帕尼600 mg组的无病生存期(DFS)。
要点
- 主要DFS分析中帕唑帕尼600 mg较安慰剂无显著获益(HR 0.86)。
- 帕唑帕尼800 mg组次要DFS分析HR 0.69(95%CI 0.51–0.94)。
- ALT、AST升高是导致停药的主要不良事件。
核心结论
- 帕唑帕尼600 mg主要DFS分析显示在辅助治疗中较安慰剂无获益。
研究设计与样本
- III期随机试验,共1,538例肾切除术后pT2(高级别)或≥pT3(含N1)透明细胞肾细胞癌患者随机接受帕唑帕尼或安慰剂1年;403例起始剂量800 mg。
- 因毒性减量,800 mg起始剂量降至600 mg,主要终点分析改为帕唑帕尼600 mg组对比安慰剂的DFS(n=1,135)。
- 主要分析在意图治疗(ITT)帕唑帕尼600 mg组(ITT600mg)累积350例DFS事件后进行,12个月后进行DFS随访分析。
- 次要终点包括ITT帕唑帕尼800 mg组(ITT800mg)的DFS与安全性。
主要发现
- ITT800mg(n=403)次要DFS分析HR 0.69(95%CI 0.51–0.94)。
- ITT600mg随访分析HR 0.94(95%CI 0.77–1.14)。
- 导致治疗中断的ALT升高在帕唑帕尼600 mg组为16%、800 mg组为18%;AST升高分别为5%和7%。
关键数值与推荐
- 帕唑帕尼800 mg组次要DFS:HR 0.69(95%CI 0.51–0.94)。
- ITT600mg随访DFS:HR 0.94(95%CI 0.77–1.14)。
- 导致停药的ALT升高:600 mg组16% vs 800 mg组18%;AST升高:600 mg组5% vs 800 mg组7%。
临床怎么用
- 原文未报告。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. Patients and Methods A total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including N1, clear cell RCC were randomly assigned to pazopanib or placebo for 1 year; 403 patients received a starting dose of 800 mg or placebo. To address toxicity attrition, the 800-mg starting dose was lowered to 600 mg, and the primary end point analysis was changed to disease-free survival (DFS) for pazopanib 600 mg versus placebo (n = 1,135). Primary analysis was performed after 350 DFS events in the intent-to-treat (ITT) pazopanib 600 mg group (ITT600mg), and DFS follow-up analysis was performed 12 months later. Secondary end point analyses included DFS with ITT pazopanib 800 mg (ITT800mg) and safety. Results The primary analysis results of DFS ITT600mg favored pazopanib but did not show a significant improvement over placebo (hazard ratio [HR], 0.86; 95% CI, 0.70 to 1.06; P = .165). The secondary analysis of DFS in ITT800mg (n = 403) yielded an HR of 0.69 (95% CI, 0.51 to 0.94). Follow-up analysis in ITT600mg yielded an HR of 0.94 (95% CI, 0.77 to 1.14). Increased ALT and AST were common adverse events leading to treatment discontinuation in the pazopanib 600 mg (ALT, 16%; AST, 5%) and 800 mg (ALT, 18%; AST, 7%) groups. Conclusion The results of the primary DFS analysis of pazopanib 600 mg showed no benefit over placebo in the adjuvant setting.
引用
- Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017. PMID: 28902533. doi:10.1200/JCO.2017.73.5324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。